JP2009524595A5 - - Google Patents

Download PDF

Info

Publication number
JP2009524595A5
JP2009524595A5 JP2008547721A JP2008547721A JP2009524595A5 JP 2009524595 A5 JP2009524595 A5 JP 2009524595A5 JP 2008547721 A JP2008547721 A JP 2008547721A JP 2008547721 A JP2008547721 A JP 2008547721A JP 2009524595 A5 JP2009524595 A5 JP 2009524595A5
Authority
JP
Japan
Prior art keywords
amount
formulation
surfactant
buffer
lysine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2008547721A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009524595A (ja
JP5247467B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2006/062297 external-priority patent/WO2007076354A2/en
Publication of JP2009524595A publication Critical patent/JP2009524595A/ja
Publication of JP2009524595A5 publication Critical patent/JP2009524595A5/ja
Application granted granted Critical
Publication of JP5247467B2 publication Critical patent/JP5247467B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2008547721A 2005-12-20 2006-12-19 安定なタンパク質製剤 Active JP5247467B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US75215005P 2005-12-20 2005-12-20
US60/752,150 2005-12-20
PCT/US2006/062297 WO2007076354A2 (en) 2005-12-20 2006-12-19 Stable protein formulations

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2011141983A Division JP5538309B2 (ja) 2005-12-20 2011-06-27 安定なタンパク質製剤

Publications (3)

Publication Number Publication Date
JP2009524595A JP2009524595A (ja) 2009-07-02
JP2009524595A5 true JP2009524595A5 (enExample) 2010-02-12
JP5247467B2 JP5247467B2 (ja) 2013-07-24

Family

ID=38057529

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2008547721A Active JP5247467B2 (ja) 2005-12-20 2006-12-19 安定なタンパク質製剤
JP2011141983A Active JP5538309B2 (ja) 2005-12-20 2011-06-27 安定なタンパク質製剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2011141983A Active JP5538309B2 (ja) 2005-12-20 2011-06-27 安定なタンパク質製剤

Country Status (24)

Country Link
US (1) US8476239B2 (enExample)
EP (1) EP1962886B2 (enExample)
JP (2) JP5247467B2 (enExample)
KR (1) KR101378194B1 (enExample)
CN (3) CN101378773B (enExample)
AR (2) AR058567A1 (enExample)
AU (1) AU2006330593B2 (enExample)
BR (1) BRPI0622256A2 (enExample)
CA (1) CA2634547C (enExample)
CL (1) CL2010000816A1 (enExample)
DK (1) DK1962886T4 (enExample)
EA (1) EA014232B1 (enExample)
ES (1) ES2436616T5 (enExample)
HR (1) HRP20131196T4 (enExample)
IL (1) IL192104A (enExample)
NO (1) NO347247B1 (enExample)
NZ (1) NZ569108A (enExample)
PE (1) PE20071063A1 (enExample)
PL (1) PL1962886T6 (enExample)
PT (1) PT1962886E (enExample)
RS (1) RS53127B2 (enExample)
SG (1) SG153832A1 (enExample)
TW (3) TW200738261A (enExample)
WO (1) WO2007076354A2 (enExample)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140186361A1 (en) 2012-09-07 2014-07-03 Coherus Biosciences, Inc. Stable Aqueous Formulations of Adalimumab
AR058568A1 (es) 2005-12-20 2008-02-13 Bristol Myers Squibb Co Metodos para producir una composicion con moleculas ctla4-ig a partir de un medio de cultivo
TW200738261A (en) * 2005-12-20 2007-10-16 Bristol Myers Squibb Co Stable protein formulations
PT2253644E (pt) 2005-12-20 2014-01-23 Bristol Myers Squibb Co Composições e métodos para a produção de uma composição
US9309316B2 (en) 2005-12-20 2016-04-12 Bristol-Myers Squibb Company Stable subcutaneous protein formulations and uses thereof
US7915222B2 (en) 2008-05-05 2011-03-29 Bristol-Myers Squibb Company Method of preventing the development of rheumatoid arthritis in subjects with undifferentiated arthritis
CN105435211A (zh) 2008-10-06 2016-03-30 三维肽胶株式会社 组织闭塞剂
EP2445616B1 (en) * 2009-06-23 2018-05-02 GE Healthcare Bio-Sciences AB Simulator device
GB201009676D0 (en) * 2010-06-10 2010-07-21 Glaxosmithkline Biolog Sa Novel process
JP5847418B2 (ja) 2011-03-30 2016-01-20 富士フイルム株式会社 細胞接着性タンパク質
EP2699258A4 (en) * 2011-04-15 2014-10-29 Us Sec Dep Of Health And Human Services AAV-mediated CTLA-4 gene transfer for the treatment of SJÖGREN SYNDROME
CA2833623A1 (en) 2011-04-20 2012-10-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Aav mediated exendin-4 gene transfer to salivary glands to protect subjects from diabetes or obesity
TWI527590B (zh) * 2011-06-17 2016-04-01 艾瑞斯貿易公司 Ｆｇｆ－１８之凍乾調配物
US8648079B2 (en) 2011-10-07 2014-02-11 Takeda Pharmaceutical Company Limited Heterocyclic compounds
SMT202000091T1 (it) 2011-10-13 2020-05-08 Bristol Myers Squibb Co Polipeptidi anticorpali che antagonizzano cd40l
US10485869B2 (en) 2011-10-18 2019-11-26 Coherus Biosciences, Inc. Etanercept formulations stabilized with meglumine
AU2012326170B2 (en) * 2011-10-18 2016-12-22 Coherus Biosciences, Inc. Etanercept formulations stabilized with metal ions
WO2014004780A1 (en) 2012-06-29 2014-01-03 Bristol-Myers Squibb Company Methods for reducing glycoprotein aggregation
EP2869903B1 (en) 2012-07-06 2018-11-28 3-D Matrix Ltd. Fill-finish process for peptide solutions
WO2014011629A1 (en) 2012-07-09 2014-01-16 Coherus Biosciences, Inc. Stable aqueous formulations of etanercept
WO2014018747A2 (en) 2012-07-26 2014-01-30 Momenta Pharmaceuticals, Inc. Glycoproteins with anti-inflammatory properties
AU2013308470B2 (en) 2012-08-31 2017-04-20 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services AAV mediated aquaporin gene transfer to treat Sjogren's syndrome
KR102250937B1 (ko) 2012-09-11 2021-05-12 코히러스 바이오사이언시즈, 인코포레이티드 고순도 및 탁월한 수율의 정확하게 폴딩된 에타너셉트
US10450361B2 (en) 2013-03-15 2019-10-22 Momenta Pharmaceuticals, Inc. Methods related to CTLA4-Fc fusion proteins
ES2708759T3 (es) 2013-05-13 2019-04-11 Momenta Pharmaceuticals Inc Procedimientos para el tratamiento de la neurodegeneración
CN103385852B (zh) * 2013-08-06 2015-03-11 南京正大天晴制药有限公司 一种盐酸法舒地尔注射液及其制备方法
IL312865B2 (en) 2013-09-11 2025-06-01 Eagle Biologics Inc Liquid protein formulations containing viscosity-lowering agents
EP3058084A4 (en) 2013-10-16 2017-07-05 Momenta Pharmaceuticals, Inc. Sialylated glycoproteins
DK3116896T3 (en) 2014-03-10 2019-03-18 3 D Matrix Ltd SELF-PREPARING PEPTIME COMPOSITIONS
ES3037364T3 (en) 2014-03-10 2025-10-01 3 D Matrix Ltd Sterilization and filtration of peptide compositions
US20170051059A1 (en) 2014-03-19 2017-02-23 Bristol-Myers Squibb Company Methods of treating transplant rejection using a domain antibody directed against cd40
RU2689145C2 (ru) * 2014-04-16 2019-05-24 Биокон Лтд. Стабильные белковые препараты, содержащие молярный избыток сорбитола
WO2015164595A1 (en) 2014-04-25 2015-10-29 Bristol-Myers Squibb Company Use of ctla4 compound for achieving drug-free remission in subjects with early ra
US11357857B2 (en) 2014-06-20 2022-06-14 Comera Life Sciences, Inc. Excipient compounds for protein processing
US10478498B2 (en) 2014-06-20 2019-11-19 Reform Biologics, Llc Excipient compounds for biopolymer formulations
WO2015196091A1 (en) 2014-06-20 2015-12-23 Reform Biologics, Llc Viscosity-reducing excipient compounds for protein formulations
EP3157947A1 (en) 2014-06-23 2017-04-26 Novartis AG Hsa-gdf-15 fusion polypeptide and use thereof
CN106573955B (zh) 2014-06-23 2021-02-26 诺华股份有限公司 位点特异性蛋白质修饰
US10588980B2 (en) 2014-06-23 2020-03-17 Novartis Ag Fatty acids and their use in conjugation to biomolecules
SG11201702614SA (en) 2014-10-01 2017-04-27 Eagle Biolog Inc Polysaccharide and nucleic acid formulations containing viscosity-lowering agents
US20180200325A1 (en) 2014-11-18 2018-07-19 Shionogi & Co., Ltd. Stabilized peptide composition
SG11201704758XA (en) 2015-01-23 2017-08-30 Novartis Ag Synthetic apelin fatty acid conjugates with improved half-life
MA41459A (fr) 2015-02-03 2017-12-12 Als Therapy Development Inst Anticorps anti-cd40l et méthodes pour traiter des maladies ou des troubles liés aux cd40l
DK3303394T3 (da) 2015-05-29 2020-07-06 Agenus Inc Anti-ctla-4-antistoffer og fremgangsmåder til anvendelse deraf
DK3347031T3 (da) * 2015-09-11 2021-04-26 Nutrition & Biosciences Usa 1 Llc Sammensætning, der omfatter et protein og en polyalkoxyfedtforbindelse
US11229702B1 (en) 2015-10-28 2022-01-25 Coherus Biosciences, Inc. High concentration formulations of adalimumab
DK3386541T3 (da) * 2015-12-07 2020-09-28 Merck Patent Gmbh Vandig farmaceutisk formulering omfattende anti-pd-1-antistof avelumab
US20190000923A1 (en) 2015-12-22 2019-01-03 Novartis Ag Methods of treating or ameliorating metabolic disorders using growth differentiation factor 15 (gdf-15)
WO2017120092A1 (en) 2016-01-06 2017-07-13 3-D Matrix, Ltd. Combination compositions
EP3192805A1 (en) 2016-01-15 2017-07-19 Humanitas Mirasole S.p.A. Inhibitors of t cell activation or stimulation and uses thereof
US11071782B2 (en) 2016-04-20 2021-07-27 Coherus Biosciences, Inc. Method of filling a container with no headspace
IL307242B1 (en) 2016-12-07 2026-07-01 Agenus Inc Anti-CTLA-4 antibodies and methods of using them
EP3630843A2 (en) 2017-05-24 2020-04-08 ALS Therapy Development Institute Therapeutic anti-cd40 ligand antibodies
WO2019123427A1 (en) 2017-12-22 2019-06-27 Novartis Ag Methods of treating metabolic disorders with fgf21 variants
CN108014338A (zh) * 2018-01-22 2018-05-11 安徽未名生物医药有限公司 一种注射用巴利昔单抗冻干粉针及其制备方法
CN112512561A (zh) * 2018-05-25 2021-03-16 雷迪博士实验室有限公司 稳定的融合蛋白制剂
CN112512562A (zh) * 2018-05-25 2021-03-16 雷迪博士实验室有限公司 CTLA4-Ig融合蛋白制剂
EP3813791A2 (en) * 2018-06-26 2021-05-05 Lupin Limited Stable lyophilized dosage form of protein
EP3814492A4 (en) * 2018-06-29 2022-02-23 Wuhan Neurophth Biotechnology Limited Company Compositions and methods for treating leber's hereditary optic neuropathy
CN113396158A (zh) 2018-11-26 2021-09-14 诺华股份有限公司 Lpl-gpihbp1融合多肽
US12703762B2 (en) 2018-12-18 2026-08-11 Novartis Ag Reversal binding agents for anti-factor XI/XIa antibodies and uses thereof
CN113508129B (zh) 2019-01-15 2025-02-18 法国国家健康和医学研究院 突变的白介素-34(il-34)多肽及其在治疗中的用途
US20220098252A1 (en) 2019-01-25 2022-03-31 Ospedale San Raffaele S.R.L. Inhibitor of dux4 and uses thereof
GB201913697D0 (en) 2019-09-23 2019-11-06 King S College London DAP10/DAP12 fusion polypeptides
JP2023507795A (ja) * 2019-12-20 2023-02-27 アントス セラピューティクス， インコーポレイテッド 第ＸＩ／ＸＩａ因子抗体の医薬製剤および投薬レジメン
GB202003277D0 (en) 2020-03-06 2020-04-22 King S College London Therapeutic agents
GB202007655D0 (en) 2020-05-22 2020-07-08 King S College London Chimeric nkg2d protein
WO2022162704A1 (en) * 2021-02-01 2022-08-04 Dr. Reddy's Laboratories Limited Compositions comprising fusion protein and analytical attributes thereof
BR112023019385A2 (pt) 2021-03-23 2023-12-05 King S College London Composições compreendendo polipeptídeos de fusão nkg2d, cxcr2 e dap10/dap12 e seus métodos de uso
CN113925963B (zh) * 2021-10-15 2023-08-11 江苏太平洋美诺克生物药业股份有限公司 一种稳定的包含抗cd147单克隆抗体的药物制剂
GB202214120D0 (en) 2022-09-27 2022-11-09 King S College London Compositions comprising NKG2D, CXCR2, and DAP10/DAP12 fusion polypeptides and methods of use thereof
KR20250054810A (ko) * 2022-09-29 2025-04-23 화이자 인코포레이티드 Rsv f 단백질 삼량체를 포함하는 면역원성 조성물
EP4389762A1 (en) 2022-12-23 2024-06-26 Ospedale San Raffaele S.r.l. Inhibitors of dux4 activity and their use in therapy.
WO2025196207A1 (en) 2024-03-20 2025-09-25 King's College London Compositions and methods for use in depleting senescent cells and treating aging
WO2026021575A1 (zh) * 2024-07-26 2026-01-29 鸿运华宁（杭州）生物医药有限公司 一种gipr抗体融合蛋白质的药用稳定溶液制剂及其应用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0686045T3 (da) * 1993-02-23 2001-03-05 Genentech Inc Stabilisering af med organisk opløsningsmiddel behandlede polypeptider med et hjælpestof
DE4405426A1 (de) 1994-02-21 1995-08-24 Boehringer Mannheim Gmbh Pharmazeutisches Präparat enthaltend Plasminogenaktivator (t-PA) oder dessen Derivate
US6267958B1 (en) * 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
CA2226575C (en) * 1995-07-27 2011-10-18 Genentech, Inc. Stabile isotonic lyophilized protein formulation
WO2003005465A1 (en) 2001-04-25 2003-01-16 Quallion, Llc Rechargeable lithium battery for tolerating discharge to zero volts
US7094874B2 (en) * 2000-05-26 2006-08-22 Bristol-Myers Squibb Co. Soluble CTLA4 mutant molecules
US7183376B2 (en) * 2000-06-23 2007-02-27 Maxygen, Inc. Variant B7 co-stimulatory molecules
US20040022787A1 (en) 2000-07-03 2004-02-05 Robert Cohen Methods for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID
CA2630062C (en) * 2000-07-03 2014-10-14 Bristol-Myers Squibb Company Methods for treating graft versus host disease and immune disorders associated with rejection using a soluble ctla4 molecule
MXPA03006699A (es) * 2001-01-26 2004-05-31 Univ Emory Metodos de induccion de tolerancia al trasplante de organos y correccion de hemoglobinopatias.
CA2466054C (en) 2001-11-13 2012-01-03 Genentech, Inc. Apo-2 ligand/trail formulations
DE10163459A1 (de) * 2001-12-21 2003-07-03 Merck Patent Gmbh Lyophilisierte Zubereitung enthaltend Antikörper gegen EGF-Rezeptor
DE10204792A1 (de) * 2002-02-06 2003-08-14 Merck Patent Gmbh Lyophilisierte Zubereitung enthaltend Immuncytokine
WO2003068260A1 (fr) 2002-02-14 2003-08-21 Chugai Seiyaku Kabushiki Kaisha Produits pharmaceutiques en solution contenant des anticorps
TWI328614B (en) 2002-12-23 2010-08-11 Bristol Myers Squibb Co Product quality enhancement in mammalian cell culture processes for protein production
EP1575998A4 (en) * 2002-12-23 2007-07-25 Bristol Myers Squibb Co PROCESS FOR CULTIVATING MAMMALIAN CELLS FOR PROTEIN PRODUCTION
PT1610820E (pt) 2003-04-04 2010-12-16 Novartis Ag Formulações de elevada concentração de anticorpos e proteínas
NZ545314A (en) * 2003-08-04 2009-03-31 Bristol Myers Squibb Co Methods for treating cardiovascular disease using a soluble CTLA4 molecule
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
CA2618068C (en) * 2005-08-05 2016-02-16 Amgen Inc. Stable aqueous protein or antibody pharmaceutical formulations and their preparation
TW200738261A (en) * 2005-12-20 2007-10-16 Bristol Myers Squibb Co Stable protein formulations

Similar Documents

Publication Publication Date Title
ES2338218T3 (es) Formulacion farmacologica liofilizada estable de anticuerpos igg daclizumab.
TWI459961B (zh) 長效人類生長激素共軛物之液態配方
CN102712677B (zh) 脂肽组合物和相关方法
ES2313881T3 (es) Formulaciones de vacunas frente al papilomavirus humano.
JP7229999B2 (ja) ダプトマイシン製剤
CN106061468B (zh) 包含TNFR和Fc区的融合蛋白的液体制剂
JP2012515221A5 (enExample)
JP2024099628A5 (enExample)
JP2008535819A5 (enExample)
JP2013500947A5 (enExample)
JP2011506442A5 (enExample)
HRP20161653T1 (hr) Liofilizirane formulacije terapeutskih peptitijela
FI3725330T3 (fi) Polypeptidien stabiilit valmisteet ja niiden käyttötarkoitukset
TWI428140B (zh) A freeze-dried preparation containing influenza vaccine and a method for producing the same
JP2019509311A5 (enExample)
JP5138699B2 (ja) Ｐｅｇ−インターフェロンアルファ接合体の配合物
TWI615158B (zh) 多肽之調配物
WO2015190378A1 (ja) 安定なアダリムマブ水性製剤
TWI243057B (en) Formulations for protection of peg-interferon alpha conjugates
ES2365832T3 (es) Composiciones que comprenden conjugados de peg-interferón alfa y rafinosa como crioprotector.
JP2008510716A (ja) Ｉｌ−１アンタゴニスト製剤
JP2024028905A (ja) ペグアスパラガーゼの凍結乾燥組成物
AU2014237111B2 (en) Recombinant factor VIII formulations
US12599669B2 (en) Use of low molecular weight polyvinylpyrrolidone (PVP) to reduce viscosity of high concentration protein formulations
RU2004133349A (ru) Жидкий препарат, содержащий производное кампототецина, и фармацевтическая композиция, получаемая путем лиофилизации препарата